Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]